Emergent BioSolutions (EBS) Non-Current Deferred Tax Liability (2016 - 2025)
Emergent BioSolutions (EBS) has 10 years of Non-Current Deferred Tax Liability data on record, last reported at $37.8 million in Q4 2025.
- For Q4 2025, Non-Current Deferred Tax Liability fell 22.7% year-over-year to $37.8 million; the TTM value through Dec 2025 reached $37.8 million, down 22.7%, while the annual FY2025 figure was $37.8 million, 22.7% down from the prior year.
- Non-Current Deferred Tax Liability reached $37.8 million in Q4 2025 per EBS's latest filing, up from $36.3 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $125.4 million in Q4 2022 and bottomed at $34.8 million in Q1 2024.
- Average Non-Current Deferred Tax Liability over 5 years is $62.0 million, with a median of $53.1 million recorded in 2021.
- Peak YoY movement for Non-Current Deferred Tax Liability: soared 114.72% in 2022, then crashed 62.36% in 2023.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $94.9 million in 2021, then soared by 32.14% to $125.4 million in 2022, then plummeted by 62.36% to $47.2 million in 2023, then increased by 3.6% to $48.9 million in 2024, then decreased by 22.7% to $37.8 million in 2025.
- Per Business Quant database, its latest 3 readings for Non-Current Deferred Tax Liability were $37.8 million in Q4 2025, $36.3 million in Q3 2025, and $46.5 million in Q2 2025.